Association of AIM, a Novel Apoptosis Inhibitory Factor, with Hepatitis via Supporting Macrophage Survival and Enhancing Phagocytotic Function of Macrophages*

Ikuko HarutaDagger , Yoichiro Kato§, Etsuko HashimotoDagger , Christina Minjares, Shawna Kennedy, Hirofumi Uto, Katsumi YamauchiDagger , Makio Kobayashi§, Sei-ichi Yusa||**, Urs Müller||, Naoaki HayashiDagger , and Toru Miyazaki||DaggerDagger

From the Dagger  Institute of Gastroenterology and § Department of Pathology, Tokyo Women's Medical University, 8-1 Kawata-cho, Shinjuku-ku, Tokyo 162-8666, Japan,  Center for Immunology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390-9093, || The Basel Institute for Immunology, Grenzacherstrasse 487, CH-4005 Basel, Switzerland, and ** Fox-Chase Cancer Center, Philadelphia, Pennsylvania 19111

Received for publication, January 12, 2001, and in revised form, March 20, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

A hallmark of many inflammatory diseases is the destruction of tissue cells by infiltrating hematopoietic cells including lymphocytes, neutrophils, and macrophages. The regulation of apoptosis of both target tissue cells and the infiltrating cells is one of the key events that defines the initiation and the progression of inflammation. However, the precise picture of the apoptosis regulation of the cells at the inflammatory sites is still unclear. We recently isolated a novel apoptosis inhibitory factor, termed AIM, which is secreted exclusively by tissue macrophages. In this report, we present unique characteristics of AIM associated with liver inflammation (hepatitis), identified by introducing an experimental hepatitis in both AIM-transgenic mice, which overexpress AIM in the body, and normal mice. First, endogenous AIM expression in macrophages is rapidly increased in response to inflammatory stimuli. Second, AIM appears to inhibit the death of macrophages in the inflammatory regions, judging by the remarkably increased number of macrophages observed in the liver from transgenic mice. In addition, we show that AIM also enhances the phagocytosis by macrophages, which emphasizes the multifunctional character of AIM. All these findings strongly provoke an idea that AIM may play an important role in hepatitis pathogenesis in a sequential manner; first AIM expression is up-regulated by inflammatory stimuli, and then in an autocrine fashion, AIM supports the survival of infiltrating macrophages as well as enhances phagocytosis by macrophages, which may result in an efficient clearance of dead cells and infectious or toxic reagents.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Apoptosis is a form of cell death that is achieved by programmed signal cascades triggered by differential stimuli depending on the variety of physiological situations (1-4). Accumulating evidence has revealed that apoptosis plays a key role in the pathology of inflammation (5-13). The present consensus is emerging that both positive (inducing) and negative (inhibiting) regulation of apoptosis of tissue cells influence the initiation and the progression of tissue damage (14-17). It has been indicated that apoptosis at the inflammatory sites seems to be induced by: 1) inflammatory cytokines produced by the infiltrating hematopoietic cells as well as the tissue epithelium cells (18-20) and 2) interaction of CD95 (also called Fas) on the tissue cells and CD95 ligand (CD95L) predominantly expressed on infiltrating T-lymphocytes (21-27). In particular, the prevention of endotoxin-induced hepatitis by the defect of CD95/CD95L ligation strongly implies that CD95-mediated apoptosis of hepatocytes is the initial event in the process of hepatitis (21). In addition to apoptosis of tissue cells, apoptosis regulation of infiltrating cells also seems to influence the progression of inflammation. This indication was recently drawn by the observation of non-obese diabetic mice, a mouse model of human autoimmune diabetes (type I diabetes), under CD95-deficient conditions, which were free from destruction of insulin-producing pancreatic beta  cells by the infiltrating T-lymphocytes. In these mice, a defect of CD95 appeared to decrease apoptotic death of T-lymphocytes infiltrating into the pancreatic Langerhans islets, resulting in the prevention of tissue damage (28, 29). Thus, the regulation of both target tissue cells and infiltrating cells influence the progression of inflammatory diseases.

However, we are essentially ignorant of the negative (inhibitory) regulation of apoptosis at the inflammatory sites, although apoptosis must be regulated both positively and negatively, and the balance of these two regulations may critically influence the inflammation progression. This is mainly because the extracellular ligands produced at the inflammatory sites that mediate inhibitory signals for apoptosis have not been well defined so far despite the recent identification of many intracellular apoptosis inhibitory elements (14-17).

We recently isolated a novel murine apoptosis inhibitory factor, termed AIM, which is exclusively secreted by tissue macrophages including Kupffer cells in the liver (30, 31). AIM inhibits apoptosis triggered by multiple stimuli including irradiation, glucocorticoid, and CD95-cross-linking (30). At the inflammatory sites of most tissues, the macrophage is one of the cell types that is observed from the very early stage of inflammation (32-36). Hence it is possible that AIM might play a role in the negative regulation of apoptosis of cells at the inflammatory sites.

In this report, we applied a mouse hepatitis model to address potential involvement of AIM in the progression of inflammation in vivo. In addition, we present a new AIM function associated with inflammation, enhancement of the phagocytic function of macrophages, and discuss the multifunctional character of AIM.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mice-- Mice were bred and maintained in a specific pathogen-free animal facility at the Basel Institute for Immunology (Basel, Switzerland) and a semi-specific pathogen-free animal facility at the Tokyo Women's Medical University (Tokyo Japan). All animal experiments were approved by the research Ethics Committee of the Tokyo Women's Medical University.

Generation of Transgenic Mice-- AIM cDNA was subcloned into the pCAGGS expression vector (37). After the removal of the vector sequence, a purified DNA fragment was microinjected into fertilized eggs of (C57BL/6 × DBA/2)F1 mice. Embryos were transferred into the oviducts of CD-1 foster mothers. Founders were screened for transgene by PCR, and the resulting transgenic founders were bred with C57BL/6 (B6) mice to generate progenies. Transgene-positive progenies were back-crossed to B6 mice. After six back-crosses, transgene-positive and -negative littermates were used for experiments.

Induction of Endotoxin-induced Fulminant Hepatitis-- Mice were immunized by 1 mg/mouse of heat-inactivated Propionibacterium acnes (Van Kampen Group, Inc., Utah) in 200 µl of phosphate-buffered saline by intravenous injection. 7 days after the immunization, each mouse was challenged by intravenous injection of 2.5 µg of lipopolysaccharide (LPS)1 in 150 µl of phosphate-buffered saline (38). At various time points after the LPS injection, mice were sacrificed, and blood and liver specimens were collected to evaluate liver damage.

In Situ mRNA Analysis and Histology-- The liver specimens were fixed in 10% formalin and embedded in paraffin. 4-µm sections were cut out and placed on silane-coated slides. These sections were subjected to in situ hybridization using digoxigenin-labeled (Roche Molecular Biochemicals) antisense-AIM cDNA probe (Ref. 30 and references therein). As a negative control, RNaseA (100 µg/ml) pretreatment was carried out before hybridization. After hybridization, sections were treated with antidigoxigenin-alkaline phosphatase, and then signals were developed by 4-nitro blue tetrazolium chloride (NTB) treatment.

The fixed liver tissues were also used for histological analysis of macrophage detection. Sections were stained with BM-8 antibody (BMA Biochemicals), which recognizes pan-monocyte/macrophages including the Kupffer cells in the liver.

Phagocytosis Assay-- 1.5 × 106 of either RAW264 cells (a mouse macrophage cell line (39), provided by RIKEN Cell Bank, Tsukuba, Japan) or mouse peritoneal macrophage cells derived from thioglycolate-stimulated C57BL/6 mice (30) were cultured for 2 h with appropriate numbers (cell:beads ratio was 25:1, according to the Ref. 41) of fluorescein isothiocyanate-labeled polystyrene latex beads (~1.95 µm in diameter; Sigma) in the presence or absence of recombinant AIM (rAIM). Culture supernatant of the AIM-transfected Chinese ovarian carcinoma cells was used as a source of rAIM (30, 31). As a control, culture supernatant of nontransfected Chinese ovarian carcinoma cells was used. After a 2-h incubation, cells were collected by using a cell scraper followed by an extensive wash with phosphate-buffered saline, then analyzed by fluorocytometry (FACScan; Becton & Dickinson).

Binding Study-- Biotinylated rAIM protein and a control protein (a transcription factor localized in the nucleus) generated by recombinant baculovirus-infected Trichoplusia ni egg cells were used for the binding study, as we described in Miyazaki et al. (30) and Yusa et al. (31). After the binding procedure of the proteins to either peritoneal macrophages or RAW264 cells, cells were analyzed using a FACScan cytometer (Becton Dickinson).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Induction of Hepatitis Strongly Up-regulated AIM Expression within Macrophage/Kupffer Cells in the Liver-- Although AIM is exclusively expressed by tissue macrophages, only part of the macrophages in the tissue express AIM, suggesting the requirement of a specific microenvironment surrounding the macrophages for AIM expression induction (30). The precise mechanism for AIM expression regulation is, however, entirely unknown. In the previous report, we demonstrated that AIM was strongly expressed within infiltrating macrophages within Bacillus Calmette Guérin-induced granulomas, which may suggest potential up-regulation of AIM expression in response to inflammatory stimuli (30). To test this possibility, we introduced the endotoxin-induced hepatitis in C57BL/6 (B6) mice by immunizing mice with P. acnes followed by LPS injection (38) and analyzed AIM expression in both resident macrophages (Kupffer cells) and infiltrating macrophages. Two hours after the LPS injection, although there was no obvious increase of BM-8-positive cells (compare Fig. 1, a and c), most of these cells revealed AIM expression when assessed by in situ mRNA analysis (Fig. 1d). This was also confirmed quantitatively by a Northern blot analysis for AIM expression by using RNA from the liver of either before or 2 h-after hepatitis induction (Fig. 1g). Thus, hepatitis induction rapidly up-regulated AIM expression in Kupffer cells. A markedly increased number of BM-8-positive cells was observed in the liver after 12 h, representing massive infiltration of macrophages into the liver (Fig. 1e). Most of these cells also expressed AIM strongly (Fig. 1f). These results support the idea that inflammatory stimuli rapidly induce AIM expression in macrophages.


View larger version (94K):
[in this window]
[in a new window]
 
Fig. 1.   Rapid up-regulation of AIM expression by hepatitis induction. Shown is in situ hybridization analysis of AIM expression (violet/dark blue signals in b, d, and f) and its comparison with immunolocalization of pan-macrophage (including Kupfer cells) antigen, BM-8 (dark yellow/brown signals in a, c, and e) in the liver from mouse before (a and b), 2 h after (c and d), and 12 h after (e and f) inducing fulminant hepatitis. a and b, AIM is expressed in few Kupffer cells. c and d, 2 h after hepatitis induction, a far increased number of Kupffer cells expressed AIM. e and f, 12 h after hepatitis induction, a large number of macrophages infiltrated in the liver (e), and they expressed AIM (f). Magnifications: a, c, e, ×100; b, d, f, ×150. g, Northern blot analysis for AIM expression. Total liver RNA was obtained from either pre- or 2-h-after-hepatitis induction. 10 µg of RNA was separated on an agarose gel, blotted, and hybridized with a 32P-labeled AIM or mouse beta -actin cDNA probe.

Increased Number of Infiltrating Macrophages in Response to Hepatitis Induction in AIM-transgenic Mice-- Rapid up-regulation of AIM expression by hepatitis induction provokes a potential involvement of AIM in hepatitis pathogenesis, either via inhibition of apoptosis or another unknown function. In particular, since macrophages show a remarkable binding capacity for AIM (Ref. 30, and see Fig. 5B this report), AIM may function on macrophages at hepatitis regions in an autocrine fashion. To obtain a clue for the possible role of AIM at inflammatory sites, we generated transgenic mice overexpressing AIM under the control of chicken beta -actin promoter and cytomegalovirus enhancer (37) (Fig. 2a). These mice overexpress AIM ubiquitously, resulting in a strikingly increased level of AIM concentration in the serum (Fig. 2b).


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 2.   AIM transgenic mice. a, transgene construct. A 1.0-kilobase (Kb) fragment of the coding sequence (cds) of AIM cDNA was subcloned into the pCAGGS expression vector, which contained cytomegalovirus (CMV) enhancer, chicken beta -actin promoter, and rabbit beta  globin exon and intron (37). b, Western blot analysis of serum from AIM-transgenic mouse or negative littermate mouse for AIM. 5 µl of serum from each type of mouse as well as 500 ng of recombinant AIM protein produced by recombinant baculovirus-infected T. ni egg cells were size-fractionated on 10% SDS-polyacrylamide electrophoresis gels, blotted on a membrane, and stained by anti-AIM monoclonal antibody (clone 3G14; Ref. 20). Signals were developed by the ECL system (Amersham Pharmacia Biotech).

Despite the high AIM level in the serum, spontaneous infiltration of macrophages was not obvious, judging by the comparable numbers of BM-8-positive cells in the liver of nonstimulated transgenic and negative littermate mice (Fig. 3, a and b). This was also the case in all other tissues, as assessed by a histological analysis (data not shown). Thus AIM doesn't appear to be involved in either chemotaxis or migration induction of cells in vivo. However, in response to hepatitis induction via endotoxin, transgenic mice apparently harbored an increased number of infiltrating macrophages in the liver than did control littermate mice (Fig. 3, c and d). In addition, many focal accumulations of macrophages were observed in the liver of transgenic mice. This accumulation was found at regions where the destruction of the liver tissue was apparent, harboring marked infiltration of lymphocytes and neutrophils (Fig. 3e). Although these accumulations of inflammatory cells were also found in control littermate mouse liver, the size and the number of them were remarkably larger in transgenic mice.


View larger version (91K):
[in this window]
[in a new window]
 
Fig. 3.   Potentially longer survival of inflammatory macrophages in AIM-transgenic mouse liver. Liver sections from AIM-transgenic mouse (a and c) and negative littermate mouse (b and d) either before or 8 h after hepatitis induction were stained by BM-8 (dark yellow/brown signals) for pan-macrophage (including Kupffer cells) antigens. There is no increase of BM-8-positive cells in transgenic mouse liver before hepatitis induction (a and b). 8 h after hepatitis induction, a markedly larger number of BM-8-positive cells were observed in transgenic mouse liver than in negative littermate mouse liver (c and d). In transgenic mouse liver, a number of accumulation of BM-8-positive cells and leukocytes were detected (e). Magnifications: a-d, ×100; e, ×200.

At inflammatory sites, macrophages are exposed to many cytokines that mediate apoptosis (18-20). Hence in AIM-transgenic mice, high doses of AIM may support survival of macrophages at inflammatory sites by inhibiting apoptosis triggered by these cytokines, resulting in seemingly increased number of infiltrating macrophages.

It is well known that CD95 (Fas)-mediated apoptosis of hepatocytes (liver cells) is an essential event of hepatitis (21). It is not likely, however, that AIM also protects hepatocytes against apoptosis, because the binding of AIM to primary hepatocytes is not obvious so far as tested by a binding study using labeled recombinant AIM (data not shown). In line with this, there was no apparent histological difference in the destruction of hepatocytes, in hepatitis-induced transgenic and negative littermate mice (data not shown). Thus AIM appears to be associated with hepatitis by supporting macrophage survival at inflammatory sites via apoptosis inhibitory effect, which may contribute to efficient clearance of dead cells and infectious or toxic reagents by macrophages. However, in certain tissues, AIM might be involved in regulating inflammation progression not only by supporting macrophage survival but also by preventing apoptosis of tissue cells.

The precise mechanism of AIM-mediated apoptosis inhibition is not clear yet. As we described in the previous reports, there was no significant difference in the expression levels of various apoptosis-inducing or -inhibiting elements, including c-FLIP, in thymocytes of AIM-/- and AIM+/+ mice, as well as in a macrophage-cell line, J774.A1, in the presence or absence of recombinant AIM (30),2 suggesting that AIM appears to inhibit apoptosis of cells not simply by modulating the expression of these known apoptosis-related molecules but by mediating an independent signaling cascade.

AIM Enhances Phagocytotic Function of Macrophages-- When analyzed histologically in a higher magnification, macrophages harbored small nuclei within the cells that probably represent nuclei from phagocytized cells. Interestingly, a significantly larger number of macrophages harbored these small nuclei in AIM-transgenic mice than in negative littermate mice. In addition, the number of these small nuclei per macrophage was apparently larger in transgenic mice (Fig. 4). Thus AIM may activate the phagocytotic function of macrophages.


View larger version (99K):
[in this window]
[in a new window]
 
Fig. 4.   Enhanced phagocytosis by macrophages in AIM-transgenic mouse liver. Liver sections from AIM transgenic mouse (a) and negative littermate mouse (b and c) 8 h after hepatitis induction were stained for BM-8 and analyzed in a high magnification (×400). A number of BM-8-positive cells, which contained more than two small nuclei derived from dead cells, were detected in transgenic mouse liver (a). In contrast, BM-8-positive cells in negative littermate mouse contained 0 or 1 small nucleus derived from dead cells (b and c).

To test this hypothesis, we determined whether AIM enhances phagocytosis by macrophages in vitro by using rAIM produced by AIM-transfected Chinese ovarian carcinoma cells (30). Either peritoneal macrophages or a macrophage-derived cell line, RAW264, both of which have binding capacity of AIM (see Fig. 5b), were incubated with fluorescein isothiocyanate-labeled polystyrene latex beads in the presence or absence of rAIM and then the number of phagocytosed beads in each cell was analyzed by a fluorocytometry (40). Fig. 5A shows the histogram of fluorescein isothiocyanate intensity from peritoneal macrophages that were incubated either in the presence (solid line) or absence (dotted line) of rAIM. There are several peaks, which represent the number of phagocytized beads in each cell. The first peak (P0) corresponds to the macrophages that had no bead. This population was far smaller in size when macrophages were incubated in the presence of rAIM (2.9% in rAIM (+) versus 13.3% in rAIM (-)), indicating most of macrophages incubated with rAIM phagocytized beads in 2 h. In the absence of rAIM, 27.1% of macrophages phagocytized a single bead (P1), 26.1% phagocytized two beads (P2), and 14.9% phagocytized three beads (P3), respectively. There seemed to be a few macrophages that had more than four beads (P4), although they did not generate obvious peaks. In contrast, the major peak was P4, when cells were incubated in the presence of rAIM; 69% of cells had more than four beads (P4 in Fig. 5A). Similar results were obtained when assessed by using a macrophage-derived cell line, RAW264. Almost twice the number of cells achieved phagocytosis of beads in 2 h when incubated with rAIM (60% of incubated cells in rAIM (+) versus 34% of incubated cells in rAIM (-)). Furthermore, the average of the intensity of FL-1-positive population was significantly higher in the rAIM+ population (rAIM(+):rAIM(-) = 42:29), indicating each cell phagocytized larger number of beads in the presence of rAIM.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 5.   AIM accelerates phagocytotic function of macrophages in vitro. A, peritoneal macrophages were incubated with fluorescein isothiocyanate (FITC)-labeled polystyrene latex beads for 2 h in the presence or absence of rAIM. Cells were then analyzed for their uptake of the beads by FACScan (Becton-Dickinson). P0-P3 correspond to the number of phagocytized beads (e.g. P3 = 3-bead uptake), and cells that have more than 4 beads together are represented as P4. In the presence of rAIM (solid line) macrophages apparently showed enhanced phagocytosis of beads as compared with cells in the absence of rAIM (dotted line). B, AIM binding capacity of peritoneal macrophages and a macrophage cell line, RAW264, are presented as log fluorescence by black histograms. The control protein bindings, which are regarded as backgrounds, are represented by white histograms. Peritoneal macrophages showed higher capacity of AIM binding than RAW264 cells.

All together AIM apparently enhances the phagocytotic function of macrophages. However, rAIM revealed more efficient enhancement in peritoneal macrophages than in RAW264 cells. This is, perhaps, due to the difference of the binding capacity for AIM between the two cell types as shown in Fig. 5B, which clearly shows the significantly higher binding capacity of peritoneal macrophages.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Inflammatory Stimuli Up-regulate AIM Expression in Macrophages-- As we previously reported (30), AIM expression regulation harbors several unique characteristics. 1) AIM expression is restricted in tissue macrophages, 2) in a tissue, AIM expression is observed in only a part of the macrophages, (3) when ex vivo macrophages are cultured on a plastic dish, AIM expression entirely disappears, (4) AIM expression in macrophages is unable to be induced in vitro by any reagents that are known to activate macrophages, including phorbol 12-myristate 13-acetate, LPS, and various cytokines. These previous observations implied that a specific microenvironment is required for AIM expression induction in macrophages (30).

In the present study, we found that inflammatory stimuli appear to induce AIM expression in vivo. Soon after hepatitis induction, most of resident macrophages (Kupffer cells) and infiltrating macrophages in the liver revealed strong expression of AIM. Since AIM expression had already been up-regulated in Kupffer cells before infiltration of leukocytes was apparent, inflammatory cytokines produced by the liver tissue cells as well as by Kupffer cells themselves might predominantly induce AIM expression at the early stage of inflammation. At the later stage of inflammation, cytokines produced by infiltrating lymphocytes may also contribute to the up-regulation of AIM expression. Nevertheless, since AIM expression in ex vivo macrophages is not induced on a plastic dish in vitro even by various inflammatory cytokines (30), inflammatory stimuli may synergies the basic mechanism of AIM expression induction, which may depend on microenvironment, e.g. cell-cell interaction between specific type of cells and macrophages. Further study will precisely clarify the elements required for AIM expression induction.

AIM Enhances Phagocytosis of Macrophages; Multifunctional Character of AIM-- We recently reported that AIM induces strong and sustained growth inhibition of B-lymphocytes in combination with TGF-beta 1 (31). Thus, other than apoptosis inhibitory effect, AIM has different functions depending on the target cell type and the combination with other cytokine(s). In line with this, we identified that AIM enhances phagocytotic function of macrophages. Contrary to the case of B-lymphocytes (31), AIM revealed two different functions on macrophages, apoptosis inhibition and enhancement of phagocytosis, without specific conditions. This multifunctional character of AIM is reminiscent of various cytokines such as interleukin-4, which activates B-lymphocyte proliferation in combination of IgM cross-linking as well as induces immunoglobulin class switching toward IgE (41).

So far, a variety of reagents is known to activate phagocytotic function of macrophages, including cytokines also secreted from macrophages, such as granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and interleukin-4 and -10 (42, 43). One might argue that enhancement of phagocytosis may be an indirect effect; AIM might induce production of such cytokines in macrophages, resulting in enhanced phagocytosis. It is, however, unlikely because we could not detect any up-regulation of expression of these cytokines in macrophages by AIM in vitro,3 although we cannot mutually exclude a possibility that AIM may induce an unknown factor(s) that may enhance phagocytosis.

Perspective-- It may be worth emphasizing that the unique characteristics of AIM that we presented in this report strongly imply the association of AIM with hepatitis in a sequential manner. First, AIM expression is up-regulated in response to inflammatory stimuli, and then, in an autocrine fashion, AIM supports the survival of infiltrating macrophages as well as activates phagocytosis by macrophages, which may result in an efficient clearance of dead cells and infectious or toxic reagents.

    ACKNOWLEDGEMENTS

We thank Dr. Sumiko Yamakawa and Itoe Okamoto Foundation for financial support, Dr. Shin Ohnishi (Tokyo, Japan) for discussions. The Basel Institute for Immunology was founded and supported by Hoffmann-La Roche Ltd, Basel Switzerland.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Dagger To whom correspondence should be addressed: Center for Immunology, The University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd., NA7200, Dallas, TX 75390-9093. Tel.: 1-214-648-7322; Fax: 1-214-648-7331; E-mail: toru.miyazaki@UTSouthwestern.edu.

Published, JBC Papers in Press, April 9, 2001, DOI 10.1074/jbc.M100324200

2 I. Haruta, C. Minjares, and T. Miyazaki, unpublished results.

3 C. Minjares, S-i. Yusa, and T. Miyazaki, manuscript in preparation.

    ABBREVIATIONS

The abbreviations used are: LPS, lipopolysaccharide; rAIM, recombinant AIM.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Minden, A., Lin, A., McMahon, M., Lange-Carter, C., Derijard, B., Davis, R. J., Johnson, G. L., and Karin, M. (1994) Science 266, 1719-1723[Medline] [Order article via Infotrieve]
2. Pombo, C. M., Bonventre, J. V., Avruch, J., Woodgett, J. R., Kyriakis, J. M., and Force, T. (1994) J. Biol. Chem. 269, 26546-26551[Abstract/Free Full Text]
3. Westwick, J. K., Bielawska, A. E., Dbaibo, G., Hannun, Y. A., and Brenner, D. A. (1995) J. Biol. Chem. 270, 22689-22692[Abstract/Free Full Text]
4. Verheij, M., Bose, R., Lin, X. H., Yao, B., Jarvis, W. D., Grant, S., Birrer, M. J., Szabo, E., Zon, L. I., Kyriakis, J. M., Haimovitz-Friedman, A., Fuks, Z., and Kolesnick, R. N. (1996) Nature 380, 75-79[CrossRef][Medline] [Order article via Infotrieve]
5. Steller, H. (1995) Science 267, 1445-1449[Medline] [Order article via Infotrieve]
6. Jacobson, M. D., Weil, M., and Raff, M. C. (1997) Cell 88, 347-354[Medline] [Order article via Infotrieve]
7. Raff, M. C. (1992) Nature 356, 397-400[CrossRef][Medline] [Order article via Infotrieve]
8. Vaux, D. L., Haecker, G., and Strasser, A. (1994) Cell 76, 777-779[Medline] [Order article via Infotrieve]
9. Thompson, C. B. (1995) Science 267, 1456-1462[Medline] [Order article via Infotrieve]
10. Cory, S. (1995) Annu. Rev. Immunol. 13, 513-543[CrossRef][Medline] [Order article via Infotrieve]
11. Yang, E., and Korsmeyer, S. J. (1996) Blood 88, 386-401[Free Full Text]
12. Strasser, A., Huang, D. C., and Vaux, D. L. (1997) Biochim. Biophys. Acta 1333, 151-178[CrossRef]
13. Chao, D. T., and Korsmeyer, S. J. (1998) Annu. Rev. Immunol 16, 395-419[CrossRef][Medline] [Order article via Infotrieve]
14. Reed, J. (1995) Curr. Opin. Oncol. 7, 541-546[Medline] [Order article via Infotrieve]
15. Rothstein, T. L. (1996) Curr. Opin. Immunol. 8, 362-371[CrossRef][Medline] [Order article via Infotrieve]
16. Nishina, H., Fischer, K. D., Radvanyi, L., Shahinian, A., Hakem, R., Rubie, E. A., Bernstein, A., Mak, T. W., Woodgett, J. R., and Penninger, J. M. (1997) Nature 385, 350-353[CrossRef][Medline] [Order article via Infotrieve]
17. Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J. L., Schroter, M., Burns, K., Mattmann, C., Rimoldi, D., French, L. E., and Tschopp, J. (1997) Nature 388, 190-195[CrossRef][Medline] [Order article via Infotrieve]
18. Benoist, C., and Mathis, D. (1997) Cell 89, 1-3[CrossRef][Medline] [Order article via Infotrieve]
19. Andre, I., Gonzalez, A., Wang, B., Katz, J., Benoist, C., and Mathis, D. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 2260-2263[Abstract/Free Full Text]
20. Wang, B., Gonzalez, A., Benoist, C., and Mathis, D. (1996) Eur. J. Immunol. 26, 1762-1769[Medline] [Order article via Infotrieve]
21. Kondo, T., Suda, T., Fukuyama, H., Adachi, M., and Nagata, S. (1997) Nat. Med. 3, 409-413[Medline] [Order article via Infotrieve]
22. Liu, W., Tan, D., Zhang, Z., Fan, X., and Ouyang, K. (2000) Chung-Hua Kan Tsang Ping Tsa Chih. 8, 269-271
23. Hahn, C. S., Cho, Y. G., Kang, B. S., Lester, I. M., and Hahn, Y. S. (2000) Virology 276, 127-137[CrossRef][Medline] [Order article via Infotrieve]
24. Taya, N., Torimoto, Y., Shindo, M., Hirai, K., Hasebe, C., and Kohgo, Y. (2000) Br. J. Haematol. 10, 89-97[CrossRef]
25. Crispe, I. N., Dao, T, Klugewitz, K., Mehal, W. Z., and Metz, D. P. (2000) Immunol. Rev. 174, 47-62[CrossRef][Medline] [Order article via Infotrieve]
26. Ogawa, S., Sakaguchi, K., Takaki, A., Shiraga, K., Sawayama, T., Mouri, H., Miyashita, M., Koide, N., and Tsuji, T. (2000) J. Gastroenterol. Hepatol. 15, 69-7513[CrossRef][Medline] [Order article via Infotrieve]
27. Ji, W., Wang, H., and Feng, C. (1999) Chung-Hua Kan Tsang Ping Tsa Chih. 7, 77-79
28. Kim, Y. H., Kim, S., Kim, K. A., Yagita, H, Kayagaki, N., Kim, K. W., and Lee, M. S. (1999) Eur. J. Immunol. 29, 455-465[CrossRef][Medline] [Order article via Infotrieve]
29. Kim, S., Kim, K. A., Hwang, D. Y., Lee, T. H., Kayagaki, N., Yagita, H., and Lee, M. S. (2000) J. Immunol. 15, 2931-2936
30. Miyazaki, T., Hirokami, Y., Matsuhashi, N., Takatsuka, H., and Naito, M. (1999) J. Exp. Med. 189, 413-422[Abstract/Free Full Text]
31. Yusa, S., Ohnishi, S., Onodera, T., and Miyazaki, T. (1999) Eur. J. Immunol. 29, 1086-1093[CrossRef][Medline] [Order article via Infotrieve]
32. Papaccio, G., De Luca, B., and Pisanti, F. A. (1998) J. Cell. Biochem. 71, 479-490[CrossRef][Medline] [Order article via Infotrieve]
33. Yoon, J. W., and Jun, H. S. (1999) Arch. Pharmacol. Res. 22, 437-447[Medline] [Order article via Infotrieve]
34. Jun, H. S., Santamaria, P., Lim, H. W., Zhang, M. L., and Yoon, J. W. (1999) Diabetes 48, 34-42[Abstract]
35. Rosmalen, J. G., Martin, T., Dobbs, C., Voerman, J. S., Drexhage, H. A., Haskins, K., and Leenen, P. J. (2000) Lab. Invest. 80, 23-30[Medline] [Order article via Infotrieve]
36. Jun, H. S., Yoon, C. S., Zbytnuik, L., van Rooijen, N., and Yoon, J. W. (1999) J. Exp. Med. 189, 347-358[Abstract/Free Full Text]
37. Niwa, H., Yamamura, K., and Miyazaki, J. (1991) Gene 108, 193-199[CrossRef][Medline] [Order article via Infotrieve]
38. Tsuji, H., Mukaida, N., Harada, A., Kaneko, S., Matsushita, E., Nakanuma, Y., Tsutsui, H., Okamura, H., Nakanishi, K., Tagawa, Y., Iwakura, Y., Kobayashi, K., and Matsushima, K. (1999) J. Immunol. 162, 1049-1055[Abstract/Free Full Text]
39. Tanida, N., Ohno, N., Adachi, Y., Matsuura, M., Nakano, M., Kiso, M., Hasegawa, A., and Yadomae, T. (1992) J. Biochem. (Tokyo) 112, 616-623[Abstract]
40. Kawaguchi, M., Ishizawa, S., Odake, H., Shimoda, F., Nakagawa, H., Mizukoshi, K., Kurashige, Y., and Koizumi, F. (1988) Acta Oto-Laryngol. Suppl. 454, 108-112[Medline] [Order article via Infotrieve]
41. Coffman, R. L., Lebman, D. A., and Rothman, P. (1993) Adv. Immunol. 54, 229-270[Medline] [Order article via Infotrieve]
42. Grzybowski, J., Oldak, E., and Janiak, M. K. (1999) Postepy Hig. Med. Dosw. 53, 75-86[Medline] [Order article via Infotrieve]
43. Smith, M. E., van der Maesen, K., and Somera, F. P. (1998) J. Neurosci. Res. 54, 68-78[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.